Nyxoah's Genio System Shows Strong Efficacy in Complete Concentric Collapse Patients

  • Nyxoah presented full 12-month data from the ACCCESS U.S. pivotal study at ISSS 2026, showing a 74.3% median reduction in AHI with Genio® bilateral stimulation in Complete Concentric Collapse (CCC) patients.
  • The study met both co-primary efficacy endpoints: 77.2% AHI responder rate and 87.7% ODI responder rate, with no device- or procedure-related serious adverse events.
  • Nyxoah submitted a PMA supplement to the FDA to expand Genio’s indication to CCC patients, a population with no commercially available neurostimulation option in the U.S.
  • Patients reported significant improvements in quality of life, with 94.7% reporting improvement and 97.4% satisfied with the implant.

Nyxoah’s positive 12-month data from the ACCCESS study positions Genio as a potential game-changer for OSA patients with Complete Concentric Collapse, a population currently underserved in the U.S. The submission of a PMA supplement to the FDA marks a critical step in expanding Genio’s market reach, potentially tapping into a significant unmet clinical need. The company’s ability to deliver on this opportunity will hinge on regulatory approval and subsequent market adoption.

Regulatory Approval
Whether the FDA will approve the PMA supplement, allowing Nyxoah to expand Genio’s indication to CCC patients in the U.S.
Market Expansion
The pace at which Nyxoah can penetrate the U.S. market with Genio, given the unmet need for neurostimulation options in CCC patients.
Clinical Outcomes
How long-term follow-up data from the ACCCESS study will impact Genio’s adoption and reimbursement landscape.